The effects of chronic oral cimetidine therapy on the cardiovascular system in man.
1 The demonstration of histamine (H2) receptors in the cardiovascular system in man and the widespread use of the specific H2 receptor antagonist cimetidine for the treatment of peptic ulcer has necessitated assessment of the cardiovascular effects of this drug during oral therapy in man. 2 Consequently, nineteen patients with a history of peptic ulcer but in symptomatic remission underwent a double-blind crossover trial of oral cimetidine v placebo, each treatment period lasting 4 weeks. No significant difference in various cardiac parameters at rest (heart rate, blood pressure, ECG) or following a maximal treadmill exercise test (time-into-protocol, maximum heart rate and blood pressure) was found between the groups. Similarly, cimetidine produced no change in the incidence of ventricular ectopics or in heart rate on 24 h ambulatory monitoring and had no effect on left ventricular volume or contractility as measured by echocardiography. 3 Thus oral administration of cimetidine in a dose of 400 mg four times daily was associated with no demonstrable cardiovascular changes. In addition, since this dose is thought compatible with cardiovascular H2 receptor blockade this study favours the lack of a physiological role for these receptors in man.
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002927:Cimetidine / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D004452:Echocardiography; D004562:Electrocardiography; D006146:Guanidines / Q000009:adverse effects*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D005082:Physical Exertion; D013276:Stomach Ulcer / Q000188:drug therapy
D006146:Guanidines; D002927:Cimetidine